Search
forResearch 10 of 230
- The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
- Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses
- Lack of efficacy of apremilast in 9 patients with severe alopecia areata
- Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders
- Apremilast for extensive and treatment-resistant alopecia areata: a retrospective analysis of five patients
- Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata
- Apremilast is efficacious in refractory alopecia areata
- Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
Community 2
Learn
— no results
Try a deeper search in learn →